We have documented, contrary to expectation, that the renin-angiotensin-aldosterone system (RAAS) is stimulated normally by restriction of sodium intake in patients with Type 2 diabetes mellitus (DM) and hypertension. Conversely, plasma renin activity (PRA) is suppressed less than in normal subjects by a highsalt diet in these patients. Increasing plasma angiotensin II (Ang II) concentration through intravenous Ang II infusion also suppresses renin release, via the short feedback loop. In this study, we sought to ascertain whether the limited renin suppression in Type 2 diabetes mellitus via high-salt intake is a unique defect or part of a more generalised abnormality of PRA suppression. We studied 38 patients with Type 2 DM and hypertension, 158 hypertensive control patients, and 61 normotensive controls. All patients were studied while in metabolic balance on a 10 mEq sodium (Na) diet. The response to the Ang II infusion at 3 ng/kg/min for 45 minutes was measured. We found that PRA fell significantly in normal subjects, from 4.
Introduction
A resurgence of interest in the state of the RAAS in patients with diabetes mellitus (DM) reflects the unambiguous success of angiotensin-converting enzyme (ACE) inhibitors in the treatment of diabetic nephropathy. Despite longstanding interest, the state of the RAAS in patients with Type 1 and Type 2 DM remains the subject of substantial debate. 1 In his extensive review, Bjork cited dozens of studies, which indicated that the RAAS could be suppressed, normal, or activated. 1 We have recently reported the finding that PRA rose normally in response to restriction of salt intake in hypertensive patients with Type 2 DM, but that suppression on a high-salt diet was limited. 2 We could identify this unambiguous abnormality in the patients with Type 2 DM because studies were performed on an identical diet, on the same meta-bolic ward, under controlled conditions. 2, 3 These studies also provided evidence to suggest that the intrarenal RAAS was activated in these patients to a greater extent than in the normal subjects.
Another important approach to suppressing PRA involves the intrarenal angiotensin-dependent short feedback loop. [4] [5] [6] Via this mechanism, angiotensin is effective in reducing renin release through its action on AT 1 -receptors directly in the juxtaglomerular apparatus. 7 In this study, we sought to probe the renin short feedback loop by using Ang II infusions to directly assess whether the abnormal renin suppression is specific to sodium homeostasis or part of a more generalised phenomenon.
Methods

Subjects
Sixty one normotensive control subjects, 158 patients with essential hypertension and 38 patients with hypertension and Type 2 diabetes were studied. All patients were Caucasian. The baseline characteristics of the groups are shown in Table 1 . Type 2 diabetes was defined by the presence of a fasting glucose greater than 140 mg/dl or a two-hour glucose concentration after a standard glucose load greater than 200 mg/dl in a patient with no history of diabetic ketoacidosis. The outpatient treatment regimen for diabetic patients was continued during the study admission. Patients with overt nephropathy were excluded.
Hypertension was defined as a systolic blood pressure greater than 140 mmHg and a diastolic blood pressure greater than 90 mmHg on at least three outpatient visits. Serum creatinine, serum electrolytes, urinalysis, 24-hour urine-free cortisol, catecholamines, and thyroid function studies were obtained. Renal vascular studies were obtained when indicated to exclude hypertension secondary to renal artery stenosis. Hypertensive medications, if used, were withdrawn at least two weeks prior to the study necessitating a low-salt diet in an ambulatory clinical centre prior to admission.
The renin status for each patient was determined in low-salt balance (10 mEq Na/day) using the PRA after 120 minutes of upright posture.The presence of low-renin hypertension was determined by a PRA of less than 2.5 ng AngI/ml/hr. were given an isocaloric diet with 10 mEq sodium, 100 mEq potassium, and 200 ml of water. Daily 24hour urine collections were measured for sodium, potassium, and creatinine.When adequate sodium balance had been achieved, the Ang II infusions were performed.
Angiotensin II infusions
The subjects were studied while lying supine after overnight recumbency. Ang II amide (Hypertensin; Ciba Geigy Corp., Pharmaceuticals Div., Summit, NJ, USA) was infused at 3 ng/kg/min for 45 minutes using an electronic infusion pump (Harvard Apparatus Co., Inc., Millis, MA, USA). Blood pressure was monitored every two to six minutes with an indirect recording sphygmomanometer (Dinamap). Blood samples were obtained at the initiation and termination of the Ang II infusion and assessed for sodium, potassium, PRA, and Ang II.
Laboratory procedures
Blood samples were collected on ice and spun immediately. Plasma was frozen until the assay was performed. Urinary and serum sodium concentrations were measured by flame photometry with lithium as an internal standard. Serum creatinine was measured by an autoanalyser technique. 8 PRA and Ang II were assayed by techniques previously described in detail. 9, 10 Statistical analysis Data are presented as the mean values with the SEM as the index of dispersion.To analyse three or more variables, ANOVA followed by Dunnett's tests for pair-wise comparisons were used (SAS statistical software). Candidate covariates were chosen by physiological relevance followed by linear regression analysis.Where appropriate,ANCO-VA was performed by least squares for age-adjustment followed by Tukey's tests.The null hypothesis was rejected for a p-value<0.05.
Results
The normal control group, essential hypertensive control, and DM groups were well matched for urinary sodium excretion and basal supine PRA on the day prior to the study ( Table 1 ).The sex distribution was not statistically different among the three groups.There was, however, a striking difference in age, body weight, and BMI among all three groups. All pair-wise comparisons were statistically significant (p<0.01). Thus, assessment of the PRA response to Ang II required analysis of age and BMI as potential contributing covariates. Similar Ang II concentrations were achieved at the end of the infusion, with the DM group tending to be slightly higher.
PRA fell significantly in response to Ang II infusion in normal subjects, from 4.0±0.33 to 2.5±0.23 ng AngI/ml/hr (p=0.0056). In patients with essential hypertension, the Ang II infusion also led to a PAPER (Figure 1a ). Age and BMI did not affect the pattern of PRA suppression. The age-adjusted LS-means are shown in Figure 1b .There was a significant negative correlation between basal PRA, delta PRA with Ang II and age (p<0.007).
In a separate analysis, the change in PRA from baseline to the end of Ang II was compared after age adjustment.The fall in PRA in the hypertensive group (0.7±0.12 ng AngI/ml/hr) was also significant (p<0.001). Again, the change in the DM group was not significant (0.39±2.7 ng AngI/ml/hr).
The mean arterial pressure response to Ang II also differed among all three groups (all pair-wise comparisons, p<0.05) with the greatest response in the DM patients, 15.5±2.02 mmHg ( Figure 2) . The hypertensive group's response was 9.5±1.06 mmHg, and the response of normal controls was 6.27±2.04 mmHg. The directly measured Ang II levels reflected this gradient of response with the DM group having the lowest basal level (30.5±2.2 pg/ml), though the differences did not reach statistical significance.
The frequency of low-PRA hypertension was not different between the control hypertensive (14.9%) and the DM groups (13.2%). There was also no significant difference in the frequency of the modulating form of hypertension 8 between the hypertensive (59%) and the DM groups (57%).
Discussion
We have demonstrated blunting of PRA suppression in response to Ang II (defective short feedback loop) in a sizeable group of hypertensive diabetics compared with normal and hypertensive control patients. Thus, the limited suppression of PRA in response to a high-salt intake identified earlier 2,3 is not an isolated phenomenon but represents a more generalised defect of PRA regulation in DM. Previous studies of the RAAS in DM have often been confounded by lack of strict control of sodium intake and posture and by failure to study normal subjects in an identical protocol. Our study, and that of Trujillo, et al. 11 , did control for these variables. They did not observe a similar blunted renin suppression in their smaller group of hypertensive diabetics. However, the decrement in PRA was clearly smaller in the DM group with quite large confidence intervals.We believe it likely that the small sample size (n=12), resulted in a Type 2 error. This study was prompted by several recent observations which, in aggregate, suggest activation of the intrarenal RAAS as a feature of Type 2 DM. In patients who are free of nephropathy, PRA is poorly suppressible by a high-salt diet.This finding is associated with a constellation of renal haemodynamic abnormalities that include an exaggerated vasodilator response to ACE inhibition compared with normal controls in a high-salt state, and a blunting of the renal vascular response to Ang II, which is correctable by ACE inhibition. 2 In patients with Type 2 DM and frank nephropathy, a setting typically associated with low PRA, there was an enhanced renal vascular response to the Ang II antagonist, irbesartan, which also strikingly increased PRA. 12 These observations suggested high intrarenal Ang II in DM and prompted our hypothesis that PRA may be poorly suppressible by infusion of Ang II, as the basal PRA already reflected the excessive influence of the endogenous intrarenal Ang II. The results of our study greatly bolster this concept, since PRA did not suppress significantly at all in contrast to the hypertensive and normotensive control groups.
Notably, the diabetic group was also hypertensive.We have previously described a blunted short feedback loop in a subgroup of patients with essential hypertension, termed non-modulators. 13 Thus, a hypertensive control group is essential. This was provided for in our study.The frequency of non-modulators was equal in both the DM group and the essential hypertensive control group.Thus, a chance enrichment in the non-modulating phenotype in the DM group can not account for our findings.
We also observed enhanced MAP response to exogenous Ang II in diabetes. Enhanced vascular responses in DM to Ang II and norepinephrine have been previously documented, but few have demonstrated further enhancement compared with hypertensive controls. 11, 14, 15 The reasons for this are a subject of current investigation, but may include the higher BP and the process of dyslipidaemia.
A potential unifying hypothesis is the effect of hyperglycaemia per se. Hyperglycaemia has been shown to alter the short feedback loop by blunting the PRA response to captopril. 16 Twelve hours of hyperglycaemia has also been shown to increase PRA in Type 1 DM. 17 Hyperglycaemia also increases diaclyglycerol directly and, thus, protein kinase-C activity, which enhances vascular reactivity. 18, 19 Impaired vascular nitric oxide production and increased release of vasoconstrictor prostaglandins have also been described in diabetes. 20 This, clearly, would explain the enhanced vascular response to Ang II observed in our DM group. Prostaglandins and nitric oxide are also local factors involved with renin release, [21] [22] [23] although their effects on the short feedback loop are unknown.
Our results are potentially confounded by the expected differences in age and BMI among the groups. Our sample size was large enough to allow for reasonable statistical adjustment.Thus, our conclusions are unaffected.
In conclusion, our study confirms and extends growing evidence that the control of the RAAS in patients with DM is altered in a fashion that is compatible with activation of the intrarenal RAAS. Failure of suppression of the RAAS by an increase in salt intake and by an increase in Ang II concentration during Ang II infusion are both compatible with continued activation of the system through an, as yet, unidentified pathway, although multiple observations suggest that hyperglycaemia participates. Precisely how hyperglycaemia does so must be the subject of further investigation.
